Zymeworks BC Inc Dossier
Qualitative Analysis
Business overview
Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. The company leverages its proprietary therapeutic platforms, including the Azymetric bispecific antibody platform, the Drug Conjugate (ADC) platform, the EFECT platform, and the ProTECT platform, to engineer highly differentiated antibody-based therapeutic candidates. Its lead product candidate is Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors, which is being developed and commercialized globally under strategic partnerships with Jazz Pharmaceuticals and BeOne Medicines. Zymeworks is transitioning its business model toward an oncology royalty platform with a robust internal discovery engine, optimizing future milestone and royalty cash flows while selectively investing in high-quality assets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic shift announced in November 2025 to pivot from a traditional biotech model of developing and commercializing its own medicines to a hybrid model focused on licensing out assets, accumulating sales royalties, and securing milestone payments. This strategy aims to reduce capital intensity and binary late-stage development risks.
Expected impact: Creates more consistent value for shareholders, reduces cash burn, and establishes a durable, profitable operating structure with a cash runway extending beyond 2028.
Leveraging proprietary platforms to expand the ADVANCE R&D strategy beyond solid tumors into autoimmune and inflammatory diseases (AIID) and hematological cancers. This includes advancing wholly-owned product candidates like ZW171, ZW191, ZW220, and ZW251 in solid tumors, and ZW1528 in respiratory inflammation.
Expected impact: Builds a diversified portfolio of high-quality, wholly-owned product candidates targeting novel pathways in areas of significant unmet medical need.
Returning excess capital to shareholders through opportunistic share repurchases to reduce outstanding share count and enhance shareholder value.
Expected impact: Thoughtfully reduces share count over time, setting the company up for higher long-term shareholder value while maintaining financial flexibility.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides $250 million in non-dilutive capital to strengthen the balance sheet, support the stock repurchase program, fund potential strategic acquisitions, and extend the cash runway beyond 2028.
Terms: Zymeworks receives $250 million through the issuance of a non-recourse royalty-backed note. Repayments are due from 30% of worldwide tiered royalties on Ziihera (zanidatamab) owed to Zymeworks by Jazz Pharmaceuticals and BeOne Medicines. Zymeworks retains 70% of the royalties, with full rights reverting once the note is fully repaid.
Jazz holds exclusive rights to develop and commercialize zanidatamab in major global territories (outside of Asia-Pacific, Australia, and New Zealand), sharing development risk and transferring late-stage clinical and commercialization costs.
Terms: Zymeworks is eligible to receive up to $440.0 million in potential near-term milestone payments related to regulatory approvals of Ziihera in GEA in the U.S., Europe, and Japan, plus tiered royalties ranging from 10% to high teens on annual sales up to $2.0 billion, and 20% on sales above $2.0 billion.
BeOne Medicines (formerly BeiGene) holds exclusive marketing and development rights to zanidatamab in Asia (excluding Japan), Australia, and New Zealand, expanding the global reach of the lead asset.
Terms: Zymeworks is eligible to receive milestone payments related to regulatory approvals in China, alongside tiered royalties ranging from mid-single to mid-double digits on annual net sales up to $1.0 billion, and 19.5% on net sales above $1.0 billion.